Puma Biotechnology Stock Performance
| PBYI Stock | USD 3.14 0.12 3.97% |
On a scale of 0 to 100, Puma Biotechnology holds a performance score of 7. The company holds a Beta of 1.75, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Puma Biotechnology will likely underperform. Please check Puma Biotechnology's maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to make a quick decision on whether Puma Biotechnology's historical price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Puma Biotechnology are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Puma Biotechnology demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.66 | Five Day Return 5.56 | Year To Date Return (32.89) | Ten Year Return (98.68) | All Time Return (78.29) |
1 | Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference | 09/03/2024 |
2 | Puma Biotechnology investors are sitting on a loss of 79 percent if they invested five years ago | 09/16/2024 |
3 | Acquisition by Jeffrey Ludwig of 66972 shares of Puma Biotechnology subject to Rule 16b-3 | 11/01/2024 |
4 | Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635 | 11/05/2024 |
5 | Puma Biotech Q3 Earnings and Revenues Surpass Estimates | 11/07/2024 |
6 | Puma Biotechnology Inc Q3 2024 Earnings Call Highlights Revenue Surge and Strategic ... | 11/08/2024 |
7 | Puma Biotechnologys Performance Is Even Better Than Its Earnings Suggest | 11/14/2024 |
8 | Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer | 11/20/2024 |
| Begin Period Cash Flow | 78.8 M |
Puma |
Puma Biotechnology Relative Risk vs. Return Landscape
If you would invest 245.00 in Puma Biotechnology on August 28, 2024 and sell it today you would earn a total of 57.00 from holding Puma Biotechnology or generate 23.27% return on investment over 90 days. Puma Biotechnology is currently generating 0.4208% in daily expected returns and assumes 4.3072% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Puma, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Puma Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Puma Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Puma Biotechnology, and traders can use it to determine the average amount a Puma Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0977
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PBYI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.31 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.42 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Puma Biotechnology is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Puma Biotechnology by adding it to a well-diversified portfolio.
Puma Biotechnology Fundamentals Growth
Puma Stock prices reflect investors' perceptions of the future prospects and financial health of Puma Biotechnology, and Puma Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Puma Stock performance.
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.0973 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 136.91 M | ||||
| Shares Outstanding | 49.09 M | ||||
| Price To Earning | 18.52 X | ||||
| Price To Book | 2.07 X | ||||
| Price To Sales | 0.61 X | ||||
| Revenue | 235.64 M | ||||
| Gross Profit | 172.94 M | ||||
| EBITDA | 44.78 M | ||||
| Net Income | 21.59 M | ||||
| Cash And Equivalents | 77.96 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 111.49 M | ||||
| Debt To Equity | 5.19 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | 1.45 X | ||||
| Cash Flow From Operations | 27.01 M | ||||
| Earnings Per Share | 0.47 X | ||||
| Market Capitalization | 148.24 M | ||||
| Total Asset | 230.53 M | ||||
| Retained Earnings | (1.35 B) | ||||
| Working Capital | 56.8 M | ||||
| Current Asset | 223.55 M | ||||
| Current Liabilities | 32.44 M | ||||
About Puma Biotechnology Performance
By evaluating Puma Biotechnology's fundamental ratios, stakeholders can gain valuable insights into Puma Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Puma Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Puma Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 41.23 | 52.69 | |
| Return On Tangible Assets | 0.13 | 0.13 | |
| Return On Capital Employed | 0.25 | 0.26 | |
| Return On Assets | 0.09 | 0.10 | |
| Return On Equity | 0.40 | 0.42 |
Things to note about Puma Biotechnology performance evaluation
Checking the ongoing alerts about Puma Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Puma Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Puma Biotechnology had very high historical volatility over the last 90 days | |
| Puma Biotechnology has a strong financial position based on the latest SEC filings | |
| About 68.0% of the company shares are owned by institutional investors | |
| Latest headline from businesswire.com: Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer |
- Analyzing Puma Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Puma Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining Puma Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Puma Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Puma Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Puma Biotechnology's stock. These opinions can provide insight into Puma Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Puma Stock analysis
When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |